Table II.
Patient outcomes
| Cohort | P - value | |||
|---|---|---|---|---|
| A (n = 3) | B (n = 9) | C (n = 4) | ||
| MF Grade (WHO) Pre-SCT (n) | ||||
| 3 | 2 | 5 | 2 | 1.000 |
| 2 | 1 | 4 | 2 | |
| 1 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | |
| MF Grade (WHO) Post-SCT (n) | ||||
| 3 | 1 | 1 | 0 | 0.053 |
| 2 | 1 | 2 | 0 | |
| 1 | 0 | 4 | 1 | |
| 0 | 0 | 0 | 3 | |
| Incidence of GVHD (n) | ||||
| Acute | 3 Grades I-III | 4 Grades I-II | 0 | 0.0365 |
| Chronic | 1 Grade III | 4 Grades I-II | 4 Grades I-II | 0.1692 |
| Incidence of transplant related infection (n) | ||||
| Bacterial | 2 | 4 | 1 | 0.8017 |
| Viral | 3 | 3 | 2 | 0.2559 |
| Fungal | 0 | 3 | 0 | 0.3571 |
| Reduction in spleen size post –SCT (%) | 17 (12-24) | 11 (16-40) | 32 (20-38) | 0.3737 |
| Time to ANC > 0.5 × 109/l (days) | 17 (13-18) | 15 (12-19) | 12.5 (12-16) | 0.2308 |
| Time to platelet count > 100 × 109/l (days) | 150 (118-198) | 152 (109-243) | 106 (94-138) | 0.5988 |
| Time to transfusion independence (days) | 148 (118-540) | 120 (110-510) | 165 (108-270) | 0.5599 |
| Degree of response at time of last follow-up (n) | ||||
| Overall Response | 0 | 4 | 4 | 0.0378 |
| Complete Response | 0 | 2 | 4 | 0.0087 |
| Partial Response | 0 | 2 | 0 | 1.00 |
| Stable Disease | 2 | 5 | 0 | 0.1692 |
| Progressive Disease | 1 | 0 | 0 | 0.1875 |
Values shown are median (range) or number of patients.
ANC: absolute neutrophil count; GVHD: graft-versus-host disease; MF: myelofibrosis; n: number of patients; SCT: stem cell transplantation; WHO: World Health Organization.